ARCANO acted as exclusive financial advisor to IVI RMA Global on its partnership with Conceivable Life Sciences to deploy the first automated IVF laboratory in the United States

Transaction rationale

- The transaction brings together IVI RMA Global, the world's leading fertility care organization, and Conceivable Life Sciences, a pioneer in robotics and physical AI applied to the IVF laboratory, combining IVI RMA's clinical excellence with AURA, the world's first automation-assisted IVF laboratory platform.

- This allliance accompanies an agreement to deploy AURA across IVI RMA's network, starting at a US clinic in 2027, with expansion planned across Europe, Latin America and the Middle East. AURA works alongside embryologists, executing hundreds of manual, operator-dependent steps with robotic precision.

- The partnership sets a new benchmark for the industry: laboratory standardization, reduced variability across centers and operators, enhanced quality control and scalability of a globally established treatment, improving access and outcomes for patients.

  • The transaction is part of the strategic partnership between IVI RMA Global and Conceivable Life Sciences to transform the future of reproductive medicine, aimed at integrating robotic automation into the IVF laboratory, reducing operational variability and raising the standard of care across IVI RMA's global network. As part of the agreement, Prof. Antonio Pellicer, Executive Chairman of IVI RMA Global, will join Conceivable's board.
  • IVI RMA Global is the world's leading fertility care organization, committed to delivering personalized, high-quality fertility care backed by science, technology and patient support. Through its growing network of clinics across Europe, the Americas and the Middle East, IVI RMA will be the first major fertility network to implement Conceivable's technology, leading the shift toward more precise, consistent and scalable reproductive medicine.
  • Conceivable Life Sciences is pioneering a new era of IVF by unifying proprietary software, robotics and optics. Its AURA platform, guided by embryologists, replaces hundreds of manual, operator-dependent steps with robotic precision, while its data intelligence platform continuously improves by capturing thousands of data points across every cycle. In ongoing pilot studies, over 100 patients have been treated, more than 1,000 eggs processed and live births achieved. Headquartered in New York with offices in London, Barcelona and Guadalajara (Mexico), its hub-and-spoke deployment model is designed to bring world-class embryology to any clinic, anywhere.

With this transaction, ARCANO continues to strengthen its position as a reference advisor in M&A and capital transactions in healthtech and life sciences, combining sector expertise and execution capabilities in cross-border deals.

Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

COFIDES invests €45 million in MCH Ibe...

by COFIDES

Managed by MCH, the fund has a target size of €500 million and focus...

Photos Stream